Reported Earnings • May 21
First quarter 2026 earnings released First quarter 2026 results: Revenue: kr2.85m (up 33% from 1Q 2025). Net loss: kr3.57m (loss widened 35% from 1Q 2025). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Announcement • Apr 23
Neola Medical AB Reports Positive Safety Results from First Clinical Pilot Study Neola Medical AB reported final results from its clinical pilot study, confirming a favorable safety profile of Neola® across the studied patient population, including very low birth weight preterm born babies. The results provide important insights that support the development of Neola® and advance the next phase of clinical and regulatory activities. The clinical pilot study confirms that Neola® is safe and well tolerated across the studied patient population, including very low birth weight preterm born babies, representing an important milestone in the clinical development program. The study has provided valuable insights into how the technology performs in a clinical setting, helping to define the optimization of the device. The product is being sharpened by introducing lung collapse detection as a key capability, providing continuous monitoring with decision support for timely intervention. The study provided important insights into signal behavior in a clinical environment, which is expected in early-stage development of novel monitoring technologies. These findings have been addressed through refinement of signal processing and optimization of the device and its clinical application. Neola Medical AB is now focusing on high-value clinical use cases, such as the detection of significant pulmonary complications, including life-threatening lung collapse (pneumothorax), where the technology is expected to provide the greatest clinical benefit. To support the continued regulatory pathway in the United States, Neola Medical AB plans to engage with the U.S. Food and Drug Administration to align on the clinical and regulatory strategy. Subject to regulatory feedback, the company intends to initiate a clinical study in preterm born babies in the United States by mid 2027. Neola Medical AB’s first clinical pilot study was conducted at the neonatal intensive care unit at Södra Älvsborgs Sjukhus in Borås, Sweden. The study evaluated the safety and performance of Neola® in continuous lung monitoring in preterm born babies. A total of 10 babies were included, with gestational age from 28 weeks and a weight between 1,000–3,000 grams. New Risk • Feb 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Earnings have declined by 8.3% per year over the past 5 years. Revenue is less than US$1m (kr8.3m revenue, or US$918k). Market cap is less than US$10m (kr72.2m market cap, or US$8.00m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Announcement • Feb 17
Neola Medical AB (publ) to Report Q3, 2026 Results on Nov 18, 2026 Neola Medical AB (publ) announced that they will report Q3, 2026 results on Nov 18, 2026 Reported Earnings • Feb 15
Full year 2025 earnings released: kr0.14 loss per share (vs kr0.14 loss in FY 2024) Full year 2025 results: kr0.14 loss per share. Revenue: kr8.33m (down 18% from FY 2024). Net loss: kr11.0m (loss widened 9.5% from FY 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden. Announcement • Jan 21
Neola Medical AB (publ), Annual General Meeting, May 28, 2026 Neola Medical AB (publ), Annual General Meeting, May 28, 2026. New Risk • Nov 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr93.5m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.3% per year over the past 5 years. Revenue is less than US$1m (kr8.3m revenue, or US$881k). Market cap is less than US$10m (kr93.5m market cap, or US$9.87m). Price Target Changed • Nov 13
Price target decreased by 25% to kr2.40 Down from kr3.20, the current price target is provided by 1 analyst. New target price is 66% above last closing price of kr1.45. Stock is down 33% over the past year. The company posted a net loss per share of kr0.14 last year. Reported Earnings • Nov 06
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr1.81m (up 3.7% from 3Q 2024). Net loss: kr2.76m (loss widened 21% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Reported Earnings • Aug 25
Second quarter 2025 earnings released: kr0.038 loss per share (vs kr0.04 loss in 2Q 2024) Second quarter 2025 results: kr0.038 loss per share. Revenue: kr2.20m (down 20% from 2Q 2024). Net loss: kr2.96m (loss widened 4.7% from 2Q 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Reported Earnings • May 22
First quarter 2025 earnings released First quarter 2025 results: Revenue: kr2.16m (down 37% from 1Q 2024). Net loss: kr2.64m (loss widened 14% from 1Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Reported Earnings • Feb 13
Full year 2024 earnings released: kr0.14 loss per share (vs kr0.16 loss in FY 2023) Full year 2024 results: kr0.14 loss per share. Revenue: kr10.4m (up 5.8% from FY 2023). Net loss: kr10.1m (loss widened 12% from FY 2023). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden. Announcement • Feb 12
Neola Medical AB (publ) to Report Q3, 2025 Results on Nov 06, 2025 Neola Medical AB (publ) announced that they will report Q3, 2025 results on Nov 06, 2025 Announcement • Feb 11
Neola Medical Receives Approval by Swedish Authorities to Initiate Clinical Pilot Study on Preterm Born Babies in Sweden Neola Medical announced approval from the Swedish Medical Products Agency (Lakemedelsverket) and the Swedish Ethical Review Authority (Etikprovningsmyndigheten) to commence clinical pilot study on preterm born babies in Sweden, with its medical device for continuous lung monitoring, Neola®. The study will evaluate the safety and performance of Neola® in preterm born babies, marking the first clinical study with Neola® on its target patient group. Additionally, the study serves as a preparatory step for the pivotal clinical study on preterm born babies In the U.S. The study will be conducted at a Swedish hospital with a total of 10 preterm born babies in neonatal intensive care. Patients with a gestational age from 28 weeks and a weight between 1000 and 3,000 grams are included in the study. The study is expected to run for approximately four months, with initiation planned in 2025. Conducting clinical studies with Neola® on it target patient population is important, as preterm born babies differ significantly from full-term newborns. Findings from this first clinical study on preterm born baby can contribute additional input to optimizing and refining Neola®, aiming to ensure it meets the specific needs of this vulnerable and unique patient group. The results will furthermore guide preparations for the pivotal U.S. clinical study that will be instrumental in supporting planned FDA application for market approval in the U.S. To initiate the clinical pilot study on pretermborn babies in Sweden, approval is required from both the Swedish Medical Products Agency (Lakemedelsverket), and the Swedish Ethical Review authority (Etikprovnings myndigheten). The received approval from both regulatory bodies now paves the way for the commencement of the clinical pilot study on pre term born babies in Sweden. Clinical study history with the technology: 2021-2022: A large investigator-initiated and independent clinical study was conducted at the INFANT Centre at Cork University Hospital in Ireland. A total of 100 full-term newborns participated in the study, and the results demonstrated that the technology is safe and well tolerated for measuring the oxygen in the lungs. Oxygen detection in the lungs was successfully achieved in all participating infants. 2015-2018: An EU-funded project, including preclinical and clinical studies on healthy full-term newborns, laid the foundation for the company's product, Neola®. An additional clinical study involving 12 full-term newborn babies was conducted in Lund. The study demonstrated clinical acceptance of the measurements and the design of the probes, which are attached to the baby's chest. 2012-2013: Clinical research studies involving a total of 32 full-term newborns were conducted, and the results demonstrate the feasibility of measuring gas in the lungs of full-term newborns. 2010: The initial lung measurements were conducted on one full-term newborn baby at Lund University Hospital. New Risk • Jan 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr22m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m (kr11m revenue, or US$996k). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (kr183.8m market cap, or US$16.6m). New Risk • Nov 21
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: kr11m (US$999k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr22m free cash flow). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m (kr11m revenue, or US$999k). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (kr190.8m market cap, or US$17.3m). Reported Earnings • Nov 07
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr1.74m (down 2.9% from 3Q 2023). Net loss: kr2.29m (loss narrowed 3.3% from 3Q 2023). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Oct 30
Neola Medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024 Neola Medical AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024 Announcement • Aug 28
Neola Medical Appoints David Folkesson as Chief Financial Officer Neola Medical has strengthened its management team, adding David Folkesson as the new Chief Financial Officer. He joins at an important stage for the company, which is currently preparing for clinical validation of Neola. Recent Insider Transactions • Aug 21
CEO & MD recently sold kr79k worth of stock On the 16th of August, Hanna Sjostrom sold around 27k shares on-market at roughly kr2.96 per share. This transaction amounted to 8.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Hanna's only on-market trade for the last 12 months. Announcement • Aug 06
Neola Medical AB (publ) to Report Q2, 2024 Results on Aug 15, 2024 Neola Medical AB (publ) announced that they will report Q2, 2024 results on Aug 15, 2024 New Risk • Jun 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr154.3m market cap, or US$14.7m). Reported Earnings • May 23
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr3.45m (up 47% from 1Q 2023). Net loss: kr2.32m (loss widened 1.4% from 1Q 2023). New Risk • Apr 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 27% per year over the past 5 years. Revenue is less than US$1m (kr9.8m revenue, or US$896k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (kr169.8m market cap, or US$15.5m). Reported Earnings • Feb 15
Full year 2023 earnings released: kr0.16 loss per share (vs kr0.40 loss in FY 2022) Full year 2023 results: kr0.16 loss per share (improved from kr0.40 loss in FY 2022). Revenue: kr9.83m (flat on FY 2022). Net loss: kr9.01m (loss narrowed 13% from FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. New Risk • Feb 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m (kr9.2m revenue, or US$866k). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (kr125.6m market cap, or US$11.9m). Recent Insider Transactions • Jan 02
Independent Director recently bought kr93k worth of stock On the 28th of December, Urban Ottosson bought around 50k shares on-market at roughly kr1.85 per share. This transaction amounted to 9.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr101k. Insiders have collectively bought kr282k more in shares than they have sold in the last 12 months. Announcement • Dec 20
Neola Medical Receives New Patent Approval in Europe for the Neola Lung Monitoring System Neola Medical has received a new patent approval in Europe for the Neola lung monitoring system. The patent specifically covers the probes that are attached to the chest and that enable continuous monitoring of the lungs. BioStock reached out to CEO Hanna Sjostrom to find out what significance the new patent has for the project. Recent Insider Transactions • Dec 18
Independent Director recently bought kr101k worth of stock On the 15th of December, Urban Ottosson bought around 65k shares on-market at roughly kr1.54 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr190k more in shares than they have sold in the last 12 months. New Risk • Nov 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (165% increase in shares outstanding). Revenue is less than US$1m (kr9.2m revenue, or US$870k). Market cap is less than US$10m (kr73.8m market cap, or US$7.01m). Reported Earnings • Aug 17
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr2.60m (up 21% from 2Q 2022). Net loss: kr2.40m (loss narrowed 19% from 2Q 2022). Recent Insider Transactions • Jun 30
Independent Chairman of the Board recently bought kr89k worth of stock On the 27th of June, Marta Xu bought around 54k shares on-market at roughly kr1.64 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Marta's only on-market trade for the last 12 months. Reported Earnings • May 21
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr2.34m (down 28% from 1Q 2022). Net loss: kr2.29m (loss widened 4.9% from 1Q 2022). Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Marta Xu is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 24
First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.19 loss in 1Q 2021) First quarter 2022 results: kr0.10 loss per share. Revenue: kr3.27m (up 89% from 1Q 2021). Net loss: kr2.18m (loss widened 8.9% from 1Q 2021). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Chairman of the Board Marta Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr0.63 loss per share (up from kr0.85 loss in FY 2020). Revenue: kr11.1m (up 280% from FY 2020). Net loss: kr6.65m (loss narrowed 1.0% from FY 2020). Revenue was in line with analyst estimates. Board Change • Dec 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Marta Xu was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Third quarter 2021 earnings released The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr3.25m (up 479% from 3Q 2020). Net loss: kr815.0k (loss narrowed 72% from 3Q 2020). Reported Earnings • Aug 20
Second quarter 2021 earnings released The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr2.39m (up 292% from 2Q 2020). Net loss: kr2.07m (loss widened 136% from 2Q 2020). Announcement • Feb 23
BioImpact Pty Ltd Secures Exclusive Distribution Rights for NEOLA® from GPX Medical BTC health announced its investee company, BioImpact Pty Ltd, has secured exclusive distribution rights from GPX Medical AB (publ) for NEOLA® in Australia, NewZealand and Singapore. NEOLA® is an innovative, safe and non-invasive medical device which continuously measures lung volume changes and oxygen gas concentration in the lungs of preterm born infants with the possibility of instantly detecting complications. This means that health care professions are alerted to problems in real time and can treat infants right away, a significant advancement in care monitoring and management of preterm infants. GPX Medical is expected to obtain Conformité Européene (CE) approval in 2023, enabling NEOLA® to be marketed and sold in Europe. Following CE approval, BTC will apply to the Therapeutic Goods Association (TGA) in Australia and Medsafe in NZ for product registration leading to commercial launch in Australia and New Zealand. In return for exclusive distribution rights, BTC will invest in product evaluation and premarket trials, enabling neonatologists to evaluate and trial NEOLA® in a clinical setting. BTC anticipates NEOLA® will be approved and available for sale in Australia within 12 months of GPX Medical achieving CE approval. Reported Earnings • Feb 18
Full year 2020 earnings released: kr0.85 loss per share (vs kr0.031 loss in FY 2019) Full year 2020 results: Net loss: kr6.72m (loss widened 158% from FY 2019). Is New 90 Day High Low • Feb 12
New 90-day high: kr5.83 The company is up 15% from its price of kr5.09 on 13 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 16% over the same period.